Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma
Abstract Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors. There are limited curable treatments available for metastatic ccRCC because this disease is unresponsive to conventional targeted systemic pharmacothera...
Guardado en:
Autores principales: | Jacob W. Greenberg, Hogyoung Kim, Ahmed A. Moustafa, Amrita Datta, Pedro C. Barata, A. Hamid Boulares, Asim B. Abdel-Mageed, Louis S. Krane |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8bcce53528064b139c18bf1570a9c148 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sunitinib for advanced renal cell cancer
por: Chris Coppin
Publicado: (2008) -
Drug interaction evaluation of [99mTc]Tc-ketoconazole uptake with ketoconazole administration in Candidiasis mice model
por: Ahmad Kurniawan, et al.
Publicado: (2021) -
Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
por: Stephan Ursprung, et al.
Publicado: (2021) -
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
por: Dolman MEM, et al.
Publicado: (2012) -
Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma
por: Stephan Ursprung, et al.
Publicado: (2021)